Literature DB >> 9590252

Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid.

D M Granoff1, A Bartoloni, S Ricci, E Gallo, D Rosa, N Ravenscroft, V Guarnieri, R C Seid, A Shan, W R Usinger, S Tan, Y E McHugh, G R Moe.   

Abstract

The poor immunogenicity of the Neisseria meningitidis group B polysaccharide capsule, a homopolymer of alpha(2-->8) sialic acid, has been attributed to immunologic tolerance induced by prenatal exposure to host polysialyated glycoproteins. Substitution of N-propionyl (N-Pr) for N-acetyl groups on the meningococcal B polysaccharide, and conjugation of the resulting polysaccharide to a protein carrier, have been reported to yield a conjugate vaccine that elicits protective Abs with minimal autoantibody activity. To characterize the protective epitopes on the derivatized polysaccharide, we isolated 30 anti-N-Pr meningococcal B polysaccharide mAbs. These Abs were heterogeneous with respect to complement-mediated bactericidal activity, fine antigenic specificity, and autoantibody activity as defined by binding to the neuroblastoma cell line, CHP-134, which expresses long-chain a(2-->8)-linked polysialic acid. Eighteen of the Abs could activate complement-mediated bacteriolysis. Seven of these 18 Abs cross-reacted with N-acetyl meningococcal B polysaccharide by ELISA and had strong autoantibody activity. Thus, N-Pr meningococcal B polysaccharide conjugate vaccine has the potential to elicit autoantibodies. However, 7 of the 18 bactericidal mAbs had no detectable autoantibody activity. These Abs may be useful for the identification of molecular mimetics capable of eliciting protective Abs specific to the bacteria, without the risk of evoking autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9590252

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood.

Authors:  Kathleen Y Dunphy; Peter T Beernink; Barbara Brogioni; Dan M Granoff
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

2.  Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.

Authors:  Monica Konar; Dan M Granoff
Journal:  Blood       Date:  2017-06-19       Impact factor: 22.113

3.  Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein.

Authors:  Serena Giuntini; Donald C Reason; Dan M Granoff
Journal:  Infect Immun       Date:  2011-11-07       Impact factor: 3.441

4.  Specificity of the immune response to a modified group B meningococcal polysaccharide conjugate vaccine.

Authors:  Samuel Moore; Esmé K Farley; Peter C Fusco; Francis Michon
Journal:  Clin Vaccine Immunol       Date:  2006-11-01

5.  De-N-acetylated sialic acid is immunogenic and elicits antibodies that are protective against Neisseria meningitidis.

Authors:  Gregory R Moe; Becca A Flitter; Jessica Y Ing; Tamara S Bhandari; Hardeep Kaur
Journal:  Vaccimonitor       Date:  2009

6.  Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.

Authors:  Serena Giuntini; Rolando Pajon; Sanjay Ram; Dan M Granoff
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

7.  The conformational properties of methyl alpha-(2,8)-di/trisialosides and their N-acyl analogues: implications for anti-Neisseria meningitidis B vaccine design.

Authors:  Austin B Yongye; Jorge Gonzalez-Outeiriño; John Glushka; Verena Schultheis; Robert J Woods
Journal:  Biochemistry       Date:  2008-11-25       Impact factor: 3.162

Review 8.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

9.  Interplay of Carbohydrate and Carrier in Antibacterial Glycoconjugate Vaccines.

Authors:  Tyler D Moeller; Kevin B Weyant; Matthew P DeLisa
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

10.  Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines.

Authors:  Monica Konar; Dan M Granoff; Peter T Beernink
Journal:  J Infect Dis       Date:  2013-05-28       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.